Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03306940
Other study ID # 14SG21
Secondary ID
Status Recruiting
Phase N/A
First received October 2, 2017
Last updated October 11, 2017
Start date October 2, 2017
Est. completion date August 31, 2018

Study information

Verified date October 2017
Source Tongji University
Contact Lingjing Jin, PhD
Phone +86 02166111310
Email 1164427300@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups. Group A received unilateral injection while group B received bilateral injection. Patients completed follow-up A researcher record facial videos and analyzed facial symmetry and completed 3 scales.


Description:

Hemifacial spasm patients who received botulinum toxin A injection were divided into two groups.Patients of unilateral group were injected to the affected side and the dose of botulinum toxin A was 2.5-3.75 units/per site. Patients of bilateral group were injected to the affected side with dose of 2.5-3.75 units/per site and the normal side was injected with dose of 1.25 units/per site.

3 scales for measurement were used.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date August 31, 2018
Est. primary completion date July 31, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- clinical diagnosis of hemifacial spasm

- Scott grading III to IV

- hemifacial spasm duration of half or more years

- last botulinum toxin A application at least 3 months before the start of the study

Exclusion Criteria:

- history of facial trauma, congenital facial asymmetry, facial nerve microsurgical decompression

- bilateral hemifacial spasm

- allergies to botulinum toxin A or to any component of the drug

- previous treatment with botulinum toxin A fewer than 3 months

- the use of drugs that could interfere with neuromuscular transmission or spasm

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Botulinum Toxin Type A
patients were injected to the normal side with dose of 1.25 units/per site

Locations

Country Name City State
China Shanghai Tongji Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Tongji University

Country where clinical trial is conducted

China, 

References & Publications (6)

Borodic GE, Cheney M, McKenna M. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg. 1992 Dec;90(6):972-7; discussion 978-9. — View Citation

Fujimura T, Hotta M. The preliminary study of the relationship between facial movements and wrinkle formation. Skin Res Technol. 2012 May;18(2):219-24. doi: 10.1111/j.1600-0846.2011.00557.x. Epub 2011 Aug 25. — View Citation

Isse NG. Endoscopic facial rejuvenation: endoforehead, the functional lift. Case reports. Aesthetic Plast Surg. 1994 Winter;18(1):21-9. — View Citation

Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol. 2013 Feb;34(2):319-24. — View Citation

Tan NC, Chan LL, Tan EK. Hemifacial spasm and involuntary facial movements. QJM. 2002 Aug;95(8):493-500. Review. — View Citation

Xiao L, Pan Y, Zhang X, Hu Y, Cai L, Nie Z, Pan L, Li B, He Y, Jin L. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment. Neurol Sci. 2016 Nov;37(11):1807-1813. Epub 2016 Jul 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sunnybrook Facial Grading System Sunnybrook Facial Grading System consists of resting symmetry, symmetry of voluntary movement and synkinesis. Total score = Symmetry of voluntary movement score - Resting symmetry score - Synkinesis score up to 6 months
Secondary Symmetry Scale for Hemifacial Spasm Symmetry Scale for Hemifacial Spasm consists of resting symmetry and symmetry of voluntary movement. Total score =Resting symmetry score + Symmetry of voluntary movement score up to 6 months
Secondary Facial Clinimetric Evaluation Scale Facial Clinimetric Evaluation Scale consists of six parts:facial movement,facial comfort,oral function,eye comfort,lacrimal control and social function. Total score = facial movement + facial comfort + oral function + eye comfort + lacrimal control + social function. up to 6 months
Secondary The effective duration of botulinum toxin A degree of amelioration in spasm and the effective duration of botulinum toxin A up to 6 months
Secondary Adverse events Adverse events, including stiff face, difficulty drinking and eating, difficulty controlling parotid and so on.The onset and duration of adverse events.Whether to take intervention to ameliorate adverse events and the efficacy of the intervention up to 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04474977 - Microvascular Decompressive Surgery for Hemifacial Spasm
Withdrawn NCT01932255 - CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap N/A
Completed NCT00210431 - Post Marketing Surveillance Study of Dysport
Completed NCT05103202 - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Unknown status NCT01726725 - Hemifacial Spasm and Desflurane N/A
Completed NCT01598961 - Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery N/A
Not yet recruiting NCT04589364 - Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients Phase 3
Completed NCT01613781 - Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery N/A
Not yet recruiting NCT06195241 - Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm Phase 4
Completed NCT03508882 - Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Phase 4
Enrolling by invitation NCT01271634 - Observe Abnormal Potential From the Offending Vessel to the Facial Muscles of HFS Patients N/A
Recruiting NCT04645277 - Magnetic Resonance Imaging Study on Patients With Hemifacial Spasm
Completed NCT03390803 - Effect of Hemifacial Spasm on Intraocular Pressure Measurement N/A
Completed NCT01728428 - A Multicenter, Observational Study to Evaluate Clinical Manifestation, Diagnosis and Treatment of Primary Hemifacial Spasm in Chinese Patients N/A
Completed NCT04621578 - Transcutaneous Electrical Acupoint Stimulation on Postoperative Dizziness in Hemifacial Spasm Patients N/A
Completed NCT00276315 - Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm Phase 3
Completed NCT02761096 - Effect of Acupuncture on Inflammation and Immune Function After Craniotomy N/A
Not yet recruiting NCT01546805 - Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm N/A
Unknown status NCT01564979 - Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm Phase 2
Completed NCT01168388 - Movement Disorder Survey in East China N/A